Matthew Pillar
Matthew Pillar is chief editor at BioProcess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies. His chief and executive editorial experience includes tenures with Software Executive, Channel Executive, Business Solutions and ISR magazines, where he routinely interviewed international technology builders and influencers. Pillar has spoken on emerging technologies and their implications at major events for leading tech vendors including NetSuite, Oracle, SAP, and others.
Connect with Pillar on LinkedIn at linkedin.com/in/matthewpillar/
ARTICLES BY MATTHEW PILLAR
- Slippery Slope: Competitive Differentiation In Biopharma
- Inside Aruvant’s Gene Therapy Manufacturing Strategy
- mAb 2.0 For Psoriatic Arthritis
- Big Bio: Inside SILS’ New Stake In Biocon
- 4 Keys To Winning FDA Breakthrough Therapy Designation
- New ADC Linker Tech Shows Efficacy, Safety Advantages
- Inside KKNA’s Uncommon D&I Success
- Resetting The Immune System With Protein Therapeutics
- Alzheimer’s Therapy Takes A Cue From Oncology
- Cell Therapy Logistics: Challenged By COVID-19
- The Precarious Promise Of Biopharma PR
- Physics To Genetics: New Treatments For Hereditary Heart Disease
- Developing A Cure For Diabetes Type 1
- What’s Behind BridgeBio’s 30+ Drug Candidates?
- Genesis Of A Gene Therapy Manufacturing Giant
- Cell Therapy Production To Clinical Administration: Addressing The Gap
- GMP Manufacturing Of RNA-Engineered Cell Therapies
- New Indications For Existing Antibodies
- Biologics Discovery: Picking Winners & Losers
- A Maverick Gene Therapy Manufacturing Strategy
- GMP CAR T Manufacturing: The Poseida Approach
- Semper Fi: What The Marines Taught A Biopharma CEO
- SOTIO’s Quest To Build A Global Biopharma
- Manufacturing A mAb For Congenital Hyperinsulinism
- Beating Herpes: Inside X-VAX’s Vaccine Candidate
This website uses cookies to ensure you get the best experience on our website. Learn more